Loading
This study found KIT mutations and amplifications in a substantial minority of mucosal, acral and chronically sun-damaged skin melanomas but almost never in ordinary skin melanoma, identifying a targetable driver for these rarer subtypes.
Analysis of 102 primary melanomas from mucosal, acral, chronically sun-damaged and non-sun-damaged sites for KIT copy number and mutations, finding KIT alterations in 39 percent of mucosal, 36 percent of acral and 28 percent of chronically sun-damaged melanomas, and none in non-sun-damaged skin melanomas.
KIT joined BRAF and NRAS as a melanoma driver and became the rationale for imatinib and nilotinib in mucosal and acral melanoma.
Shares Acral melanoma, Mucosal melanoma, Journal of Clinical Oncology.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.